Idiopathic Parkinson's Disease Clinical Trial
Official title:
A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease
Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD) Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended dose by stereotactic intrastriatal implantation
Status | Not yet recruiting |
Enrollment | 9 |
Est. completion date | July 31, 2027 |
Est. primary completion date | September 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 70 Years |
Eligibility | Inclusion Criteria: - Provision of signed and dated informed consent form - Aged 45 to 70 years old (inclusive) at Screening - Idiopathic Parkinson's disease patients who meet the diagnostic criteria of the "Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease" - With at least 5 years since the diagnosis of Parkinson's disease - With responsiveness to levodopa or dopa agonist. This is defined as improvement between ''Off'' and ''On'' MDS-UPDRS by at least 33% of the Motor MDS-UPDRS - Idiopathic Parkinson's disease of Stage 3 ~ 4 of modified Hoehn & Yahr staging during ''ON'' time - Stable Parkinsonian medications for at least 2 months prior to the Screening Visit - MRI not showing gross atrophy or any brain pathology other than PD - Mini-Mental State Examination (MMSE) ? 24 - With score of the Beck Depression Inventory (BDI-II) < 29 and Hamilton Rating Scale for Depression (HAM-D-17) < 25 Exclusion Criteria: - Atypical or secondary Parkinsonism - With neurodegenerative disorders other than PD - Unable to receive MRI or PET scanning - With any concomitant disorder that would contraindicate coagulation, general anesthesia, or stereotactic neurosurgery - Received any other investigational agent within 4 weeks prior to Screening - History of intracranial surgeries or implantation of a device for Parkinson's disease 2 years prior to Screening - Major surgery within the previous 6 months at Screening - Significant cardiovascular disease, including: - New York Heart Association (NYHA) class III or IV congestive heart failure - Uncontrolled hypertension: Blood pressure >140/90 mmHg - History of serious ventricular arrhythmia - Malignancy within 2 years prior to Screening - Any diagnosis of autoimmune disease or immune compromised state and requiring systemic steroid or immunosuppressive treatment - Any other severe systemic disorder, including history of schizophrenia or other psychotic disorders, stroke, seizure, traumatic brain injury, or central nervous system infection, which judged by the investigator that entering the trial may be detrimental to the subject - Psychiatric, addictive or any other disorder that compromises ability to give a truly informed consent and perform all study assessments - Positive in any of the following regulatory authority-licensed screening tests: - HIV antigen/antibody combo test - Anti-HCV test - Hepatitis B surface antigen (HBsAg) test - Rapid plasma reagin (RPR) test - HIV-1 nucleic acid test (NAT) - HBV NAT - HCV NAT - Any of the following hematologic abnormalities: - Hemoglobin < 9.0 g/dL, - ANC < 1,500/µL - Platelets < 100,000/µL - Any of the following serum biochemistry abnormalities: - Total bilirubin > 1.5 × ULN - AST or ALT > 2.5 × ULN - r-GT > 2.5 × ULN - ALP > 2.5 × ULN - serum albumin < 3.0 g/dL - creatinine > 1.5 × ULN - Female subject who is lactating or has positive serum or urine pregnancy test at Screening Visit - Female subject with childbearing potential or male subject with female spouse/partner with childbearing potential who refuses to adopt at least two forms of birth control (at least one of which must be a barrier method) from Screening until Final/Early Termination Visit. Acceptable forms include: - Established use of oral, injected or implanted hormonal methods of contraception - Placement of an intrauterine device (IUD) or intrauterine system (IUS) - Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) - With any condition judged by the investigator that entering the trial may be detrimental to the subject |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Taiwan Mitochondrion Applied Technology Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grading of Adverse Events | Grading will be assessed using NCI CTCAE, version 5.0. | within 48 weeks after MitoCell transplantation | |
Primary | Routine physical examinations | Safety of Mitocell will be assessed by routine physical examinations. Physical examination conducted in this study will include general appearance, skin, eyes, ears, nose,throat, head and neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal,neurological, etc. | within 48 weeks after MitoCell transplantation | |
Primary | Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell] | Clinical standard neurological examination by study investigator. Changes in motor function, sensory function, cranial nerve function (visual fields), cortical functions and reflexes are followed in the examination, scored as normal - abnormal without clinical relevance - abnormal with clinical relevance | within 48 weeks after MitoCell transplantation | |
Primary | Changes in vital signs: blood pressure [Safety of Mitocell] | Changes in blood pressure during the study , measured as systolic and diastolic blood pressure (in mmHg) | within 48 weeks after MitoCell transplantation | |
Primary | Changes in vital signs: pulse rate [Safety of Mitocell] | Changes in pulse rate during the study (in beats per minute) | within 48 weeks after MitoCell transplantation | |
Primary | Changes in vital signs: body temperature [Safety of Mitocell] | Changes in body temperature during the study (in degrees celsius) | within 48 weeks after MitoCell transplantation | |
Primary | Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell] | Changes in laboratory variables for haematology: hemoglobin (g/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance" | within 48 weeks after MitoCell transplantation | |
Primary | Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell] | Changes in laboratory variables for haematology: Platelet count (10E9/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance" | within 48 weeks after MitoCell transplantation | |
Primary | Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell] | Changes in laboratory variables for haematology: Cell counts (10E9/L) for total WBC, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance" | within 48 weeks after MitoCell transplantation | |
Primary | Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell] | Changes in laboratory variables for haematology: INR (standardized prothrombin time) to determine the effects of oral anticoagulants on the clotting system. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance" | within 48 weeks after MitoCell transplantation | |
Primary | Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell] | Changes in laboratory variables for haematology: aPTT (sec) . Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance" | within 48 weeks after MitoCell transplantation | |
Primary | Electrocardiogram (ECG) | Safety of Mitocell will be assessed by any clinically significant abnormalities on ECG results as compared to Baseline. A standard 12-lead ECG was measured by using ECG machine that automatically measured PR, QRS, QT, and QTcF intervals. | within 48 weeks after MitoCell transplantation | |
Primary | Magnetic Resonance Imaging (MRI) | Safety of Mitocell will be assessed by any clinically significant abnormalities on MRI scans as compared to Baseline. | within 48 weeks after MitoCell transplantation | |
Secondary | MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale) | Change in MDS-UPDRS motor (Part III) "OFF" score compared to the baseline. All items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function). | at 12, 24, 48 weeks | |
Secondary | Modified Hoehn & Yahr staging | Change in Modified Hoehn & Yahr staging compared to the baseline. | at 12, 24, 48 weeks | |
Secondary | 18F-DOPA PET | Degree of radiotracer uptake increment/decrement shown on striatum of 18F-DOPA PET compared to the baseline. | at 48 weeks | |
Secondary | levodopa equivalent daily dose (LEDD) | Reduction of Parkinson's medications consumption by calculating levodopa equivalent daily dose (LEDD) compared to the baseline. | at 12, 24, 48 weeks | |
Secondary | PDQ-39 (Parkinson's Disease Questionnaire) | Change in PDQ-39 scale compared to the baseline. The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty. | at 12, 24, 48 weeks | |
Secondary | Beck Depression Inventory (BDI-II) scores | Net change from baseline in BDI-II scores. BDI-II Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represents a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe). Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression. | at 48 weeks | |
Secondary | Hamilton Depression Rating Scale (HAM-D-17) scores | Net change from baseline in HAM-D-17 scores. The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed). | at 48 weeks | |
Secondary | Mini Mental State Examination (MMSE) Scores | Net change from baseline in MMSE scores. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment. | at 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03665493 -
Dopamine Effect on Inhibitory Control
|
N/A | |
Completed |
NCT02227355 -
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01026428 -
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
|
Phase 1/Phase 2 | |
Completed |
NCT00664157 -
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
|
N/A | |
Completed |
NCT04524143 -
The Acute Effect of Cervical Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT05107531 -
Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
|
||
Completed |
NCT04524182 -
The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT00985517 -
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01968031 -
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
|
Phase 3 | |
Completed |
NCT01970813 -
Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease
|
N/A | |
Completed |
NCT01221948 -
Vercise Implantable Stimulator for Treating Parkinson's Disease
|
Phase 2 | |
Terminated |
NCT01028586 -
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
|
Phase 3 | |
Completed |
NCT00239564 -
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02240030 -
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
|
Phase 3 | |
Completed |
NCT00605683 -
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
|
Phase 3 | |
Completed |
NCT00400634 -
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
|
Phase 2 | |
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Completed |
NCT02565628 -
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT01617135 -
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
|
Phase 2 | |
Completed |
NCT01606670 -
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
|